ArticleBMC microbiology2020
Screening and identification of BP100 peptide conjugates active against Xylella fastidiosa using a viability-qPCR method.
Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- From Genome Inspection to Precision Agrochemicals: A Structure-Based Antivirulence Roadmap for Sustainable Crop Protection againstJournal of agricultural and food chemistry · 2026Review
- Specific monitoring of viable plant growth-promoting Bacillus velezensis PH-023 in the rhizosphere of tomato.BMC microbiology · 2026Article
- Synergistic Biocontrol ofInternational journal of molecular sciences · 2025Article
- Chemical Treatments Tested AgainstPathogens (Basel, Switzerland) · 2025Review
- Synthetic lipopeptides that interact with lipopolysaccharides are potent bactericidal compounds againstApplied and environmental microbiology · 2025Article
- Insight into biological strategies and main challenges to control the phytopathogenic bacteriumFrontiers in plant science · 2025Review
- Preliminary transcriptomic analyses revealFrontiers in microbiology · 2025Article
- A reliable qPCR technique for detecting viable Xanthomonas arboricola pv. pruni cells.Applied microbiology and biotechnology · 2024Article
- Prunus dulcis response to novel defense elicitor peptides and control of Xylella fastidiosa infections.Plant cell reports · 2024Article
- Synergistic antibacterial activity ofFrontiers in microbiology · 2024Article
- Nisin-based therapy: a realistic and eco-friendly biocontrol strategy to contrastFrontiers in microbiology · 2024Article
- Colonization and population dynamics of total, viable, and culturable cells of two biological control strains applied to apricot, peach, and grapevine crops.Frontiers in microbiology · 2023Article
- Bactericidal and plant defense elicitation activities of Eucalyptus oil decrease the severity of infections byFrontiers in plant science · 2023Article
- Article
- Synthetic Peptides against Plant Pathogenic Bacteria.Microorganisms · 2022Review
- Thidiazuron: New Trends and Future Perspectives to FightAntibiotics (Basel, Switzerland) · 2022Review
- Evaluation of Three Antimicrobial Peptides Mixtures to Control the Phytopathogen Responsible for Fire Blight Disease.Plants (Basel, Switzerland) · 2021Article
- Review
- Article
- Antimicrobial Peptides With Antibiofilm Activity AgainstFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundXylella fastidiosa is one of the most harmful bacterial plant pathogens worldwide, causing a variety of diseases, with huge economic impact to agriculture and environment. Although it has been extensively studied, there are no therapeutic solutions to suppress disease development in infected plants. In this context, antimicrobial peptides represent promising alternatives to traditional compounds due to their activity against a wide range of plant pathogens, their low cytotoxicity, their mode of action that make resistance more difficult and their availability for being expressed in plants.
resultsPeptide conjugates derived from the lead peptide BP100 and fragments of cecropin, magainin or melittin were selected and tested against the plant pathogenic bacteria X. fastidiosa. In order to screen the activity of these antimicrobials, and due to the fastidious nature of the pathogen, a methodology consisting of a contact test coupled with the viability-quantitative PCR (v-qPCR) method was developed. The nucleic acid-binding dye PEMAX was used to selectively quantify viable cells by v-qPCR. In addition, the primer set XF16S-3 amplifying a 279 bp fragment was selected as the most suitable for v-qPCR. The performance of the method was assessed by comparing v-qPCR viable cells estimation with conventional qPCR and plate counting. When cells were treated with peptide conjugates derived from BP100, the observed differences between methods suggested that, in addition to cell death due to the lytic effect of the peptides, there was an induction of the viable but non-culturable state in cells. Notably, a contact test coupled to v-qPCR allowed fast and accurate screening of antimicrobial peptides, and led to the identification of new peptide conjugates active against X. fastidiosa.
conclusionsAntimicrobial peptides active against X. fastidiosa have been identified using an optimized methodology that quantifies viable cells without a cultivation stage, avoiding underestimation or false negative detection of the pathogen due to the viable but non-culturable state, and overestimation of the viable population observed using qPCR. These findings provide new alternative compounds for being tested in planta for the control of X. fastidiosa, and a methodology that enables the fast screening of a large amount of antimicrobials against this plant pathogenic bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.